Philogen (PHIL) Q3 2024 earnings summary

Executive summary

• Provided a comprehensive update on scientific and clinical pipeline progress, with financial results to be disclosed after the full-year report in March/April next year.

• Net financial position as of September 30, 2024, is positive at €42.96 million, supporting ongoing clinical and industrial activities.

• Focused on late-stage clinical programs for antibody-based therapeutics and small molecule products, highlighting both green (antibody-cytokine fusions) and blue (small molecule) pipelines.

• Commercial agreements with Sun Pharma for Nidlegy™ and Fibromun expected to reduce internal sales costs and provide significant net sales shares.

• Revenues for 2024 projected to be approximately three times higher than 2023 (€25 million), with a strong year-end financial position anticipated.

Significant events and developments

• Successful completion of phase III trial for Nidlegy in Europe for melanoma and non-melanoma skin cancers; marketing authorization application filed with EMA in June.

• Ongoing pivotal trials in the US for Nidlegy, with pre-BLA meeting scheduled with FDA.

• DUNCAN phase II trials in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) completed enrollment, showing ~50% complete response rate in BCC.

• New global licensing agreement with Sun Pharma for Fibromun, with a 45/55 revenue split post-commercial launch.

• Approval and implementation of 2024-2026 and 2027-2029 Stock Grant Plans and 2024-2026 Director Stock Ownership Plan.

Outlook and guidance

• Expectation to finish the year with record profits and a robust pipeline, with all IPO promises delivered or exceeded.

• Year-end 2024 revenues expected to reach about €75 million, tripling 2023 results, with a further strengthened net financial position.

• Anticipated completion of phase I for ACP3 in 2025, with registration trials to start in 2026.

• Increased investments planned in clinical trials and production capacity for both small molecules and biologics.